A meta-analysis of 187 trials shows that Paxlovid and remdesivir reduce the risk for hospitalization in patients with mild-to ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

Tocilizumab significantly reduced 28-day mortality and length of ICU stay in patients with severe COVID-19 pneumonia and low S-spike nAb titers.

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

New research finds that nearly half of the racial and ethnic disparities in outpatient COVID-19 antiviral prescriptions stem ...

China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, ...

Because COVID-19 is caused by a virus, antibiotics cannot be used to treat it. However, Pulia says physicians may feel they are erring on the safe side by assuming the patient could also have ...

Vaccination against COVID-19 is crucial for individuals with multiple sclerosis (MS), ensuring safety and effectiveness despite immunosuppressive therapies.

Health ministry has issued statement highlighting that extensive studies by ICMR and AIIMS, New Delhi have established there ...

On Monday, Moderna published the results of a late-stage study of mRNA-1010, its seasonal flu vaccine. In a phase 3 clinical ...

In a Phase 3 study, the company’s mRNA-1010 flu ... to daily life and work After consulting the Food and Drug Administration, Moderna withdrew its application last month for a dual flu and COVID-19 ...

A commonly prescribed medication used to counteract lung cancer therapy side effects could be minimizing a cancer treatment’s efficacy, according to research from Los Angeles-based Keck Medicine of ...